Where does C4 Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), C4 Therapeutics, Inc. ranks #10,567 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does C4 Therapeutics, Inc. hold?

C4 Therapeutics, Inc. holds 29 US utility patents granted between 2020 and 2025, spanning 6 technology areas.

What is C4 Therapeutics, Inc.'s Innovation Score?

C4 Therapeutics, Inc. has an Innovation Score of 52.9 out of 100 (top 9% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does C4 Therapeutics, Inc. focus on?

C4 Therapeutics, Inc.'s top technology area is C07D (Heterocyclic Compounds) with 29 patents, ranking #285 of 3,165 assignees active in that subclass. Grants appear in 6 CPC subclasses total.

Is C4 Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for C4 Therapeutics, Inc..

What does claim depth mean for C4 Therapeutics, Inc.'s patents?

C4 Therapeutics, Inc.'s patents average 20.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the C4 Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

C4 Therapeutics, Inc.

USPTO PatentsView assignee record - 29 granted patents across 6 technology areas, recorded in grant years 2020–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, C4 ranks #10,567 of 49,997 tracked US assignees by granted-patent volume, with 29 patents across 6 technology areas.

#10,567
of 49,997 US assignees by volume: Top 9%
by Innovation Score (52.9/100): 20.9
avg claims per patent

USPTO PatentsView assignee plate

Corpus R10567 · US Corporation #10,567 · 29 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-SMALL 29 grants
UPPER-Q #10,567/49,997
PHOTO-FINISH Brain Tunnelgenix
CPC-NARROW C07D · 6 areas
INNOV-PAR 52.9/100
CLAIMS-DENSE 20.9 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2020–2025 · 6y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Brain Tunnelgenix Technologies Corp. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How C4’s 52.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 11.7 pts (22%) Velocity 20.0 pts (38%) Breadth 8.7 pts (16%) Claim depth 12.5 pts (24%)

Qualcomm Incorporated · highest

85
C4 Therapeutics · this assignee

53
Mbda France · near

53
Rochester Institute… · near

53
Toshiba Digital… · near

53
United Therapeutics · near

53
3D Lighting… · lowest

7

What this shows C4's Innovation Score is 52.9/100 (top 9% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for C4?

Each dot is one of C4’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). C4’s own 20.9 claims/patent is ABOVE the 17.5 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

C4 vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where C4's grants concentrate

C4 Therapeutics, Inc. is a focused PatentsView assignee: 6 CPC subclasses with 100% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2024 (8 grants) versus a trough of 2 in 2021. By volume, C4 sits between Brain Tunnelgenix Technologies Corp. and Celltrion Inc..

C4's three-year grant acceleration

C4 Therapeutics, Inc. shows 20 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Brain Tunnelgenix

29
British Broadcast…

29
C N R S

29
C3 Nano

29
Calgon Carbon

29
Calithera Bioscie…

29
Cbrite

29
Celltrion

29
C4 Therapeutics ◀

29

What this shows C4 holds 29 patents at rank #10,568, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near C4

By rank, the assignees closest to #10,568 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in C4's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for C4, neither rank-band nor same-CPC leaders (those blocks stay above). In C07D (Heterocyclic Compounds), C4 ranks #285 of 3,165 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (53 here).

Mbda France 53 Rochester Institute of Technology 53 United Therapeutics Corporation 53 Toshiba Digital Solutions Corporation 53

C4's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

53 Top 9% higher than 91% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2020–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table

C4 Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2020	3	10.3%
2021	2	6.9%
2022	5	17.2%
2023	7	24.1%
2024	8	27.6%
2025partial year	4	13.8%

Which technologies does C4 Therapeutics, Inc. patent most?

C07D - Heterocyclic Compounds 29

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 20

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 15

Y02A - Technologies FOR Adaptation TO Climate Change 6

C07K - Peptides 2

G07F - Coin-freed OR Like Apparatus 2

Top 6 of 6 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

C4 Therapeutics, Inc.'s patent record in context - here's where to go next.

C4 Therapeutics, Inc.'s lead technology class is C07D (Heterocyclic Compounds), 100% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #10,567 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare C4 Therapeutics, Inc. against Brain Tunnelgenix Technologies Corp., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 52.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.